Chelsea Bolyard
Biochemistry, Genetics and Molecular Biology · The Ohio State University
Publications
112
Citations
1,268
Est. group size
~30
Recurring co-author estimate
Active years
15
Publishing since 2011
Chelsea Bolyard's research focuses on oncolytic virus therapy, particularly using modified herpes simplex virus (HSV-1) to selectively infect and kill cancer cells, especially in brain tumors like glioblastoma. Their work also explores ways to combine these viral therapies with other treatments, such as bortezomib (a cancer drug) or immune-boosting strategies involving natural killer (NK) cells, to improve tumor-killing effectiveness.
Publication output was modest and fluctuating from 2017-2021, then increased sharply in 2022-2023 before dropping off in 2024-2025.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- Supplementary Figure Legend from Bortezomib Treatment Sensitizes Oncolytic HSV-1–Treated Tumors to NK Cell Immunotherapy
2023
- Supplementary Figures from Bortezomib Treatment Sensitizes Oncolytic HSV-1–Treated Tumors to NK Cell Immunotherapy
2023
- Supplementary Figures from Bortezomib Treatment Sensitizes Oncolytic HSV-1–Treated Tumors to NK Cell Immunotherapy
2023
- Supplementary Figure Legend from Bortezomib Treatment Sensitizes Oncolytic HSV-1–Treated Tumors to NK Cell Immunotherapy
2023
- Data from Bortezomib Treatment Sensitizes Oncolytic HSV-1–Treated Tumors to NK Cell Immunotherapy
2023
- Data from Bortezomib Treatment Sensitizes Oncolytic HSV-1–Treated Tumors to NK Cell Immunotherapy
2023
- Therapeutic Application of Brain-Specific Angiogenesis Inhibitor 1 for Cancer Therapy
Cancers · 2021
- Enhancing Antitumor Efficacy of Heavily Vascularized Tumors by RAMBO Virus through Decreased Tumor Endothelial Cell Activation
Cancers · 2020
- Emergency Department “Bounce-Back” Rates as a Function of Emergency Medicine Training Year
Cureus · 2020
- Suppression of HMGB1 Released in the Glioblastoma Tumor Microenvironment Reduces Tumoral Edema
Molecular Therapy — Oncolytics · 2018
- Humanized chondroitinase ABC sensitizes glioblastoma cells to temozolomide
The Journal of Gene Medicine · 2017
- Sex as a biological variable in response to temozolomide
Neuro-Oncology · 2017
- Bortezomib Treatment Sensitizes Oncolytic HSV-1–Treated Tumors to NK Cell Immunotherapy
Clinical Cancer Research · 2016
- 656. Effects of STAT3 Inhibition on the Innate Immune Response to OV Therapy
Molecular Therapy · 2016
- 520. Arming a Tumor Targeted Oncolytic HSV Vector with MMP9 for Enhanced Distribution and Killing Activity
Molecular Therapy · 2016
- Cancer Research×7
- Neuro-Oncology×3
- Regular and Young Investigator Award Abstracts×3
- Journal of Hematology & Oncology×2
- Clinical Cancer Research×2
- Jack Hedberg
Biochemistry, Genetics and Molecular Biology · The Ohio State University
- Kimerly Powell
Biochemistry, Genetics and Molecular Biology · The Ohio State University
- Kevin A. Cassady
Biochemistry, Genetics and Molecular Biology · The Ohio State University
- Anna Bratasz
Biochemistry, Genetics and Molecular Biology · The Ohio State University
- Piotr Hadaczek
Biochemistry, Genetics and Molecular Biology · The Ohio State University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 19, 2026.
Claim or correct this profile